Marina Picillo

List of Publications by Citations

Source: https://exaly.com/author-pdf/1928542/marina-picillo-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers4,390
citations38
h-index60
g-index171
ext. papers5,412
ext. citations4.3
avg, IF5.24
L-index

#	Paper	IF	Citations
162	Freezing of gait and executive functions in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 395-400	7	223
161	Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. <i>Human Mutation</i> , 2013 , 34, 1208-15	4.7	208
160	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 781-7	3.6	177
159	Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. <i>Journal of Neurology</i> , 2015 , 262, 425-34	5.5	126
158	The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic lerminals. <i>EMBO Journal</i> , 2017 , 36, 1392-1411	13	124
157	The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. <i>PLoS ONE</i> , 2013 , 8, e70244	3.7	118
156	The relevance of gender in Parkinson's disease: a review. <i>Journal of Neurology</i> , 2017 , 264, 1583-1607	5.5	106
155	Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms. <i>Brain Stimulation</i> , 2016 , 9, 425-437	5.1	100
154	Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. <i>Brain</i> , 2009 , 132, 2350-5	11.2	92
153	Regional gray matter atrophy in patients with Parkinson disease and freezing of gait. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1804-9		89
		4.4	
152	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26	3.6	86
152 151	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective		86
	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26 Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. <i>Movement</i>	3.6	
151	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26 Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. <i>Movement Disorders</i> , 2013 , 28, 1391-7 Validation of the Italian version of the Movement Disorder SocietyUnified Parkinson's Disease	3.6 7	86
151 150	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26 Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. <i>Movement Disorders</i> , 2013 , 28, 1391-7 Validation of the Italian version of the Movement Disorder SocietyUnified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7 PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. <i>Neurogenetics</i> ,	3.6 7 3.5	86 8 ₅
151 150 149	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26 Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. <i>Movement Disorders</i> , 2013 , 28, 1391-7 Validation of the Italian version of the Movement Disorder SocietyUnified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7 PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. <i>Neurogenetics</i> , 2014 , 15, 183-8 Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.	3.6 7 3.5 3	86 85 84

(2014-2018)

145	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology, The</i> , 2018 , 17, 597-608	24.1	68
144	Hearing impairment in Parkinson's disease: expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012 , 27, 1530-5	7	67
143	Gender differences in non-motor symptoms in early, drug naWe Parkinson's disease. <i>Journal of Neurology</i> , 2013 , 260, 2849-55	5.5	61
142	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014 , 261, 2319-28	5.5	61
141	Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. <i>Movement Disorders</i> , 2009 , 24, 689-96	7	61
140	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016 , 39, 405-1	21.1	58
139	A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. <i>Movement Disorders</i> , 2010 , 25, 800-2	7	58
138	The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. <i>European Journal of Neurology</i> , 2016 , 23, 1673-1679	6	55
137	Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018 , 265, 2602-2613	5.5	53
136	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. <i>Journal of Neurology</i> , 2013 , 260, 714-40	5.5	52
135	Gait patterns in Parkinsonian patients with or without mild cognitive impairment. <i>Movement Disorders</i> , 2012 , 27, 1536-43	7	52
134	Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms. <i>Brain Stimulation</i> , 2016 , 9, 438-452	5.1	50
133	Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients. <i>Neurology</i> , 2017 , 89, 776-784	6.5	49
132	Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015 , 22, 253-60	6	48
131	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. Journal of Neurology, 2012 , 259, 1808-13	5.5	47
130	Serotonergic pathology and disease burden in the premotor and motor phase of A53T Esynuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology, The</i> , 2019 , 18, 748-759	24.1	44
129	Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014 , 27, 276-81	3.8	43
128	Gender differences in non-motor symptoms in early Parkinson's disease: a 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 850-4	3.6	43

127	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 137-40	3.6	43
126	Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 462-71	1	40
125	Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. <i>Journal of Neurology</i> , 2013 , 260, 438-44	5.5	39
124	Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. <i>Movement Disorders</i> , 2011 , 26, 1303-9	7	38
123	Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2015 , 22, 93-8	6	37
122	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 373-8	7	36
121	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020 , 35, 2106-2111	7	35
120	Quality of Life and Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 499-516	4.4	34
119	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014 , 35, 379-83	3.5	34
118	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naMe Parkinson's disease. <i>Journal of Neurology</i> , 2013 , 260, 1724-30	5.5	34
117	Low-frequency Subthalamic Stimulation in Parkinson's Disease: Long-term Outcome and Predictors. <i>Brain Stimulation</i> , 2016 , 9, 774-779	5.1	33
116	Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-nalle Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 802-7	6	32
115	Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. <i>Cell Death and Disease</i> , 2018 , 9, 385	9.8	31
114	Predictors of deep brain stimulation outcome in tremor patients. <i>Brain Stimulation</i> , 2018 , 11, 592-599	5.1	31
113	Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 275-81	3.8	31
112	The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017 , 24, 788-795	6	29
111	Subthreshold depression and subjective cognitive complaints in Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 541-4	6	29
110	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 89-92	3.6	29

(2016-2014)

109	Dopamine transporter availability in motor subtypes of de novo drug-nalle Parkinson's disease. Journal of Neurology, 2014 , 261, 2112-8	5.5	28
108	Interleaving Stimulation in Parkinson's Disease, Tremor, and Dystonia. <i>Stereotactic and Functional Neurosurgery</i> , 2018 , 96, 379-391	1.6	25
107	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 37, 106-110	3.6	23
106	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 256-9	3.6	23
105	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. Journal of Neurology, 2018 , 265, 2211-2220	5.5	22
104	Recent advances in Essential Tremor: Surgical treatment. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S171-5	3.6	21
103	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 772-5	3.6	21
102	Serum IGF-1 is associated with cognitive functions in early, drug-nalle Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0186508	3.7	21
101	Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1041	- 8 .6	20
100	Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 127-31	3.8	20
99	Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. <i>Journal of Neural Transmission</i> , 2015 , 122, 1533-40	4.3	20
98	Increased bilirubin levels in de novo Parkinson's disease. European Journal of Neurology, 2015 , 22, 954-9	96	19
97	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 1399-1402	4.3	19
96	White matter changes and the development of motor phenotypes in de novo Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2016 , 367, 215-9	3.2	19
95	Subdural Continuous Theta Burst Stimulation of the Motor Cortex in Essential Tremor. <i>Brain Stimulation</i> , 2015 , 8, 840-2	5.1	19
94	Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology,</i> Neurosurgery and Psychiatry, 2020 , 91, 98-103	5.5	19
93	The language profile of progressive supranuclear palsy. <i>Cortex</i> , 2019 , 115, 294-308	3.8	18
92	Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 626-34	1	18

91	Dopamine receptor agonists and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 4, S81-4	3.6	18
90	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 116-119	3.6	18
89	Motor, cognitive and behavioral differences in MDS PSP phenotypes. <i>Journal of Neurology</i> , 2019 , 266, 1727-1735	5.5	17
88	Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy. <i>JAMA Neurology</i> , 2014 , 71, 104-7	17.2	17
87	MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes. <i>Movement Disorders</i> , 2018 , 33, 1361-1365	7	16
86	Quitting smoking: an early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 216-20	3.6	15
85	Deep Brain Stimulation Target Selection for Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 3-8	1	14
84	Exploring risk factors for stuttering development in Parkinson disease after deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2017 , 38, 85-89	3.6	14
83	Dystonia as complication of thalamic neurosurgery. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 232-2	2 36 6	13
82	The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 1327-1333	6	13
81	Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation. <i>Neurogenetics</i> , 2017 , 18, 175-178	3	13
80	Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK-2. <i>Movement Disorders</i> , 2009 , 24, 303-5	7	12
79	Parkinsonism due to A53E Bynuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. <i>Movement Disorders</i> , 2018 , 33, 1950-1955	7	12
78	How does smoking affect olfaction in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014 , 340, 215-7	3.2	11
77	Evolution of neuropsychological profile in motor subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020 , 70, 67-73	3.6	11
76	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 448-454	5.5	11
75	Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 125-128	2.2	10
74	Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. <i>European Journal of Neurology</i> , 2019 , 26, 1212-1218	6	10

73	Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family. <i>Journal of Neurology</i> , 2014 , 261, 823-4	5.5	10
72	Serum miR-30c-5p is a potential biomarker for multiple system atrophy. <i>Molecular Biology Reports</i> , 2019 , 46, 1661-1666	2.8	10
71	Serum uric acid is associated with apathy in early, drug-naWe Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016 , 123, 371-7	4.3	9
70	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson Disease 2020 ,		9
69	Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 46, 243-252	2.6	9
68	Patients with Parkinson's disease and scans with (predominant) ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013 , 260, 2405-6	5.5	8
67	Impact of COVID-19 on neurological patients attending a botulinum toxin service. <i>Neurological Sciences</i> , 2021 , 42, 433-435	3.5	8
66	Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation. <i>Functional Neurology</i> , 2018 , 33, 31-35	2.2	8
65	Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 132-138	1	7
64	Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. <i>Clinical Otolaryngology</i> , 2014 , 39, 53-7	1.8	7
63	Progressive Supranuclear Palsy-Like Phenotype in a E326K Mutation Carrier. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 444-446	2.2	6
62	From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 272-273	3.6	6
61	Parkinson's disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 495-508	4.3	6
60	The role of disease duration and severity on novel clinical subtypes of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 73, 31-34	3.6	6
59	Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020 , 72, 49-55	3.6	6
58	Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy. <i>PLoS ONE</i> , 2019 , 14, e0223621	3.7	6
57	Early MRI findings in acquired hepatocerebral degeneration. <i>Neurological Sciences</i> , 2013 , 34, 589-91	3.5	6
56	Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania. <i>Journal of Parkinsonts Disease</i> , 2014 , 4, 123-8	5.3	6

55	Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2015 , 350, 103-4	3.2	5
54	Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. <i>Journal of Alzheimerts Disease</i> , 2020 , 76, 341-347	4.3	5
53	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 184-187	2.2	5
52	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. <i>Scientific Reports</i> , 2021 , 11, 9297	4.9	5
51	Two indications, one target: Concomitant epilepsy and Tourettism treated with Centromedian/parafascicular thalamic stimulation. <i>Brain Stimulation</i> , 2017 , 10, 711-713	5.1	4
50	Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report. <i>Annals of Internal Medicine</i> , 2017 , 166, 379-380	8	4
49	Effects of gender on cognitive and behavioral manifestations in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020 , 127, 925-934	4.3	4
48	Non-Motor Correlates of Smoking Habits in de Novo Parkinson's Disease. <i>Journal of Parkinsonts Disease</i> , 2015 , 5, 913-24	5.3	4
47	Pallidal stimulation in atypical pantothenate kinase-associated neurodegeneration: six-year follow-up. <i>Movement Disorders</i> , 2014 , 29, 276-7	7	4
46	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy. <i>Neurological Sciences</i> , 2019 , 40, 2163-2169	3.5	3
45	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 9-10	3.6	3
44	A Novel Phenotype Associated with -Related Familial Brain Calcifications. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 701-703	2.2	3
43	When shaking during standing points to hereditary spastic paraplegias. <i>Parkinsonism and Related Disorders</i> , 2018 , 46, 92-94	3.6	3
42	Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 652-662	2.2	3
41	Deep brain stimulation of the ventralis oralis anterior thalamic nucleus is effective for dystonic tremor. <i>Parkinsonism and Related Disorders</i> , 2020 , 81, 8-11	3.6	3
40	Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2020 , 11, 603161	4.1	3
39	-Related Corticobasal Syndrome: Expanding the List of Corticobasal Degeneration Look Alikes. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 849-851	2.2	3
38	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2021 , 11, 8936	4.9	3

(2020-2021)

37	Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review. <i>Cells</i> , 2021 , 10,	7.9	3
36	Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy. <i>Brain and Behavior</i> , 2021 , 11, e2344	3.4	3
35	Low-Frequency Stimulation of Globus Pallidus Internus for Axial Motor Symptoms of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 445-446	2.2	2
34	Theory of Mind in multiple system atrophy: comparison with Parkinson's disease and healthy subjects. <i>Journal of Neural Transmission</i> , 2020 , 127, 915-923	4.3	2
33	Medical Management of Movement Disorders. <i>Progress in Neurological Surgery</i> , 2018 , 33, 41-49	1.4	2
32	Comment on Szewczyk-Krolikowski et al.: the influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1319-20	3.6	2
31	Serpentine tongue in long-term metoclopramide treatment. <i>Neurology Psychiatry and Brain Research</i> , 2014 , 20, 93-95	2.1	2
30	Segmental progression of cardinal motor symptoms in Parkinson's disease: a pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1143-8	3.6	2
29	Teaching NeuroImages: pseudo-abnormal DaTscan findings in meningioma-induced parkinsonism. <i>Neurology</i> , 2013 , 80, e147	6.5	2
28	Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy. <i>Scientific Reports</i> , 2021 , 11, 21683	4.9	2
27	The "zig-zag" sign in Progressive Supranuclear Palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 86-8	73.6	2
26	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. <i>Aging and Mental Health</i> , 2021 , 25, 1998-2002	3.5	2
25	Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. Journal of Parkinsonism and Restless Legs Syndrome, 2016 , 1		2
24	Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report. <i>BMC Neurology</i> , 2021 , 21, 17	3.1	2
23	Cutaneous sensory and autonomic denervation in progressive supranuclear palsy. <i>Neuropathology and Applied Neurobiology</i> , 2021 , 47, 653-663	5.2	2
22	Efficacy of Safinamide and Gender Differences During Routine Clinical Practice <i>Frontiers in Neurology</i> , 2021 , 12, 756304	4.1	2
21	Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 737-738	2.2	1
20	Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists. <i>Neurological Sciences</i> , 2020 , 41, 3361-3363	3.5	1

19	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019 , 40, 2587-2594	3.5	1
18	Movement disorders as presenting symptoms of AIDS. <i>Basal Ganglia</i> , 2013 , 3, 175-178		1
17	Step length predicts executive dysfunction in Parkinson disease: a 3-year prospective study 2018 , 265, 2211		1
16	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 82-90	3.6	1
15	Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 672-680	7	1
14	Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome <i>Neurological Sciences</i> , 2022 , 1	3.5	O
13	Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults. <i>Neurological Sciences</i> , 2021 , 1	3.5	0
12	Bipolar Disorder and Parkinson's Disease: A I-Ioflupane Dopamine Transporter SPECT Study. <i>Frontiers in Neurology</i> , 2021 , 12, 652375	4.1	О
11	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. Frontiers in Neurology, 2021 , 12, 674495	4.1	0
10	The language profile in multiple system atrophy: an exploratory study. <i>Journal of Neural Transmission</i> , 2021 , 128, 1195-1203	4.3	O
9	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2021 , 12, 711358	4.1	O
8	Childhood-onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations. <i>European Journal of Neurology</i> , 2020 , 27, e66-e67	6	
7	Corticobasal Degeneration Reveals Its Signature by Tau Strains. <i>Movement Disorders</i> , 2020 , 35, 934	7	
6	Comment on Numao et al.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 680-1	3.6	
5	Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 413-416	2.2	
4	Evolution of mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2014 , 82, 1384	6.5	
3	Energy expenditure, body composition and dietary habits in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2021 , 1	5.5	
2	Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP-RS and vPSP. <i>Movement Disorders</i> , 2021 , 36, 2449-2451	7	

Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study.. *Parkinsonism and Related Disorders*, **2022**, 98, 72-74

3.6